Key result
Initiation of PAH-specific treatment decreased the proportion of patients with any inpatient admission from 42% to 30% (P < 0.001), offsetting increased pharmacy costs.
Why the study?
Does initiation of PAH-specific treatment reduce healthcare utilization and costs in patients with pulmonary arterial hypertension?
Population
3,908 patients with pulmonary arterial hypertension identified in the Truven Health MarketScan Commercial…
Comparison
Initiation of PAH-specific treatment assessed… vs 6-month pre-treatment period.
Design
Cohort
Follow-up
6 months
Authors
Loading...
PAH treatment initiation offsets higher pharmacy costs via fewer hospitalizations; leaves open whether initial combination regimens alter total real-world spending.
Observational (n=3,908)
Does initiation of PAH-specific treatment reduce healthcare utilization and costs in patients with pulmonary arterial hypertension?
Absolute Event Rate: 30% vs 42%
p-value: p=<0.001
Initiation of PAH-specific therapy is associated with a significant decrease in inpatient admissions and nonpharmacy medical costs, which offsets the increased pharmacy costs, resulting in stable total healthcare costs.
Burger et al. (2018) conducted an observational in Pulmonary Arterial Hypertension (n=3,908). PAH-specific treatment initiation vs. 6-month pre-treatment period was evaluated on any inpatient admission (p=<0.001). Initiation of PAH-specific treatment decreased the proportion of patients with any inpatient admission from 42% to 30% (P < 0.001), offsetting increased pharmacy costs.